Pennington-based OncoSec Medical Inc. on Friday announced it appointed Robert Arch as CEO and president.
Arch has over 28 years of experience, extending from academia to the pharmaceutical industry. He was previously head of research at Elpiscience Biopharma from October 2019 to June 2021 and head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019.
Arch’s leadership roles have been focused on shaping strong teams and building diversified research & development pipelines with innovative assets, from ideas to late-stage clinical development programs. He has also held positions at Takeda, GlaxoSmithKline and Pfizer.
“On behalf of the board of directors, we are excited to welcome Robert to OncoSec and confident he will bring a focus on long-term value creation,” Kevin Smith, board member of OncoSec, said. “Robert is uniquely qualified based on his executive experience in leading cross-functional pipeline strategy and building and leading discovery teams across multiple geographic regions throughout his career.”
“I am grateful for the opportunity to join OncoSec and excited to advance (product) TAVO and the intratumoral platform technology,” Arch said. “I am honored to lead our team in our mission to bring truly novel immunotherapies to patients.”
